Oblon’s Biotechnology practice group includes skilled and talented patent agents and attorneys with scientific and industrial experience, many of whom hold doctorates in microbiology, biochemistry, immunology, molecular genetics, molecular biology and life sciences, to help our clients navigate the difficult divide between science and the law.  The group has assisted clients in worldwide prosecution, reexamination, due diligence, litigation, interferences, and acquisitions.  Our group also has expertise in drafting and obtaining plant utility patents, plant patents and PVP certificates for our clients. Due to the nature of the wide range of clients from large multi-national companies to start ups, the group has the experience of providing expert legal services to facilitate the wide-ranging business goals of such differing entities.

Our clients enjoy direct access to the group’s seasoned attorneys who clearly understand their challenges, and more importantly, their technology. In addition to our sophisticated technical backgrounds, our clients enjoy a streamlined, cost-effective approach. Our Alexandria, Virginia location adjacent to the United States Patent and Trademark Office (USPTO) enables us to regularly meet face-to-face with USPTO Patent Examiners, enhancing our ability to obtain protection for our clients' inventions while keeping cost to a minimum. Our close working relationship with the USPTO is an important factor contributing to our record of success in obtaining patent protection for our clients.

We have the resources and experience to formulate and execute global patent protection strategies for our clients, regularly appearing on their behalf in the USPTO, before the International Trade Commission (ITC), and courts throughout the United States.

Friday, June 14, 2013

Supreme Court Holds cDNA, But Not Isolated Genes, Patentable

 A unanimous Supreme Court issued its decision yesterday in the closely-watched Myriad case, Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S.

Thursday, August 16, 2012

A 2-1 split panel of the Federal Circuit issued its decision today in the closely-watched Myriad case, Association for Molecular Pathology v. Myriad Genetics, Inc., __ F.3d __ (Fed. Cir. 2012) (Lourie, J.).

Background of the Case

Myriad originated in the...